anti ccl9 Search Results


affinity-purified rabbit anti-murine ccl9 (mip-1γ) antibody  (PeproTech)
90
PeproTech affinity-purified rabbit anti-murine ccl9 (mip-1γ) antibody
Relative gene expression for osteoclast-associated genes, chemokines, and chemokine receptors
Affinity Purified Rabbit Anti Murine Ccl9 (Mip 1γ) Antibody, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/affinity-purified rabbit anti-murine ccl9 (mip-1γ) antibody/product/PeproTech
Average 90 stars, based on 1 article reviews
affinity-purified rabbit anti-murine ccl9 (mip-1γ) antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Relative gene expression for osteoclast-associated genes, chemokines, and chemokine receptors

Journal:

Article Title: Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1?) in osteoclastogenesis in vivo and in vitro

doi: 10.1182/blood-2005-08-3365

Figure Lengend Snippet: Relative gene expression for osteoclast-associated genes, chemokines, and chemokine receptors

Article Snippet: For studies of in vivo inhibition of osteoclast differentiation by anti-CCL9, tl / tl rats were injected at 20 days after birth with 50 μg affinity-purified rabbit anti-murine CCL9 (MIP-1γ) antibody (Peprotech, Rocky Hill, NJ) in 100 μL PBS, and again on days 21 and 23, with 50 μg anti-CCL9 plus 10 6 U CSF-1 in 100 μL PBS.

Techniques: Expressing, Microarray

CCL-9 and CCR1 mRNA expression in long bones determined by microarray and real-time PCR. tl rats were treated for the days indicated and total bone RNA was analyzed. CCL9 and CCR1 mRNA were highest after 2 days of treatment, after which the levels subsided. Means + 1 SD are shown. Compared with untreated animals (day 0), all time points were significantly elevated. (A-B) *Difference from day 0, P < .01. (C) *Difference from day 0, P < .005; **P < .02.

Journal:

Article Title: Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1?) in osteoclastogenesis in vivo and in vitro

doi: 10.1182/blood-2005-08-3365

Figure Lengend Snippet: CCL-9 and CCR1 mRNA expression in long bones determined by microarray and real-time PCR. tl rats were treated for the days indicated and total bone RNA was analyzed. CCL9 and CCR1 mRNA were highest after 2 days of treatment, after which the levels subsided. Means + 1 SD are shown. Compared with untreated animals (day 0), all time points were significantly elevated. (A-B) *Difference from day 0, P < .01. (C) *Difference from day 0, P < .005; **P < .02.

Article Snippet: For studies of in vivo inhibition of osteoclast differentiation by anti-CCL9, tl / tl rats were injected at 20 days after birth with 50 μg affinity-purified rabbit anti-murine CCL9 (MIP-1γ) antibody (Peprotech, Rocky Hill, NJ) in 100 μL PBS, and again on days 21 and 23, with 50 μg anti-CCL9 plus 10 6 U CSF-1 in 100 μL PBS.

Techniques: Expressing, Microarray, Real-time Polymerase Chain Reaction

Inhibition of CCL9 blocks osteoclast differentiation in vitro. Rat BMCs were induced to differentiate into osteoclasts using CSF-1 and RANKL. Anti-CCL9 antibody blocked the formation of TRAP-positive, multinucleated cells. Means + 1 SD are shown. For both antibody concentrations tested, the decrease was highly significant. *P < .001.

Journal:

Article Title: Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1?) in osteoclastogenesis in vivo and in vitro

doi: 10.1182/blood-2005-08-3365

Figure Lengend Snippet: Inhibition of CCL9 blocks osteoclast differentiation in vitro. Rat BMCs were induced to differentiate into osteoclasts using CSF-1 and RANKL. Anti-CCL9 antibody blocked the formation of TRAP-positive, multinucleated cells. Means + 1 SD are shown. For both antibody concentrations tested, the decrease was highly significant. *P < .001.

Article Snippet: For studies of in vivo inhibition of osteoclast differentiation by anti-CCL9, tl / tl rats were injected at 20 days after birth with 50 μg affinity-purified rabbit anti-murine CCL9 (MIP-1γ) antibody (Peprotech, Rocky Hill, NJ) in 100 μL PBS, and again on days 21 and 23, with 50 μg anti-CCL9 plus 10 6 U CSF-1 in 100 μL PBS.

Techniques: Inhibition, In Vitro

Injections of anti-CCL9 suppress osteoclast differentiation in vivo. tl/tl rats were injected either with CSF-1 alone or with anti-CCL9 antibody and CSF-1, and TRAP+ osteoclasts were counted on multiple sections of the proximal femur from 3 animals for each condition after 4 days of injections. Anti-CCL9 significantly reduced the osteoclastogenic response to CSF-1 injections. Means + 1 SD are shown. In both areas, differences were highly significant (*P < .001).

Journal:

Article Title: Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1?) in osteoclastogenesis in vivo and in vitro

doi: 10.1182/blood-2005-08-3365

Figure Lengend Snippet: Injections of anti-CCL9 suppress osteoclast differentiation in vivo. tl/tl rats were injected either with CSF-1 alone or with anti-CCL9 antibody and CSF-1, and TRAP+ osteoclasts were counted on multiple sections of the proximal femur from 3 animals for each condition after 4 days of injections. Anti-CCL9 significantly reduced the osteoclastogenic response to CSF-1 injections. Means + 1 SD are shown. In both areas, differences were highly significant (*P < .001).

Article Snippet: For studies of in vivo inhibition of osteoclast differentiation by anti-CCL9, tl / tl rats were injected at 20 days after birth with 50 μg affinity-purified rabbit anti-murine CCL9 (MIP-1γ) antibody (Peprotech, Rocky Hill, NJ) in 100 μL PBS, and again on days 21 and 23, with 50 μg anti-CCL9 plus 10 6 U CSF-1 in 100 μL PBS.

Techniques: In Vivo, Injection